Congress funds uterine fibroid screening for underserved women
H.R. 4392 — Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 · Filed by Shontel Brown (D-OH) · 54 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to fund research on early detection of uterine fibroids and award grants to states for screening programs, patient navigation, and public awareness campaigns. It prioritizes funding for geographic areas with socially vulnerable populations at elevated risk, and requires biennial reports to Congress on findings and research developments.
Why we flagged it
The bill's core mechanism is straightforward: federal funding for state-level screening programs and research into uterine fibroid detection and treatment disparities. It is a public-health measure with explicit equity focus, not a regulatory change or industry carve-out.
What the text implies
- By prioritizing socially vulnerable populations, the bill implicitly acknowledges and attempts to address documented racial disparities in uterine fibroid diagnosis and treatment — a health equity signal that may drive broader gynecological-care equity conversations.
- Funding for 'patient navigation services' may expand non-clinical support roles in healthcare, potentially creating new workforce categories and training pathways in underserved regions.
The full analysis lists 3 implications of this text.
Who stands to gain
state health departments; academic medical centers and research institutions; gynecological imaging equipment manufacturers